Compass Therapeutics (CMPX) Registration Filing summary

Company overview and business model

• Clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics targeting angiogenesis, immune system, and tumor growth pathways.

• Pipeline includes three clinical-stage candidates and one expected to enter clinical development in 2026.

• Product candidates are designed for both standalone and combination therapies based on clinical and nonclinical data.

Financial performance and metrics

• As of September 30, 2025, 177,572,498 shares of common stock were outstanding; no preferred stock was outstanding.

• Net tangible book value as of September 30, 2025, was $210 million, or $1.18 per share.

• After a $100 million offering at $5.17 per share, as adjusted net tangible book value would be $1.56 per share, with immediate dilution of $3.61 per share to new investors.

Use of proceeds and capital allocation

• Net proceeds intended for commercial readiness, R&D, pipeline expansion, potential acquisitions or investments, working capital, and general corporate purposes.

• No current commitments for acquisitions; management retains broad discretion over allocation.

• Pending use, proceeds may be invested in short-term, investment-grade instruments or held as cash.